Our Development Pipeline

We are also in the preclinical stages of evaluating TMB-003 (topical / subcutaneous ET-A receptor antagonist) for the treatment of Localized Scleroderma. Timber expects to submit an Investigational New Drug (IND) application in Q4 2021. TMB-003 may qualify for a Rare Pediatric Disease Priority Review Voucher.

If you are interested in any of Timber’s ongoing clinical research programs, please contact trials@timberpharma.com.

​